This $895,779 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a research project by Northwestern University focused on advancing the science of metastases to the brain in breast cancer patients. The key objectives are:
-
Understanding the fundamental biology of HER2+ breast cancer metastases to the brain through genetic analysis of patient tissue samples.
-
Advancing real-time visualization of cancer cells and neural stem cells targeting HER2+ brain metastases.
-
Applying targeted neural stem cell delivery of trastuzumab analogs to suppress the growth of HER2+ brain metastases.
The research aims to improve understanding of how cancer cells invade and spread through the brain, and explore the potential of genetically engineered stem cells as a delivery mechanism for anti-HER2 therapies targeting brain metastases from breast cancer. The project will be conducted by the Northwestern University Sponsored Research Division over a 7-year period from August 2024 to July 2031.
Generated 2/25/25, 4:05 AM